Log In
BCIQ
Print this Print this
 

carbidopa/levodopa (Numient, Rytary) (IPX066)

Also known as: second generation carbidopa/levodopa (GSK587124) (formerly Patrome)

  Manage Alerts
Collapse Summary General Information
Company Impax Laboratories Inc.
DescriptionExtended-release capsule formulation of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an aromatic amino acid
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat advanced Parkinson's disease (PD); Treat idiopathic Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation U.S. - Special Protocol Assessment (Treat Parkinson's disease (PD));
U.S. - Undisclosed Review (Treat idiopathic Parkinson's disease (PD));
EU - Standard Review (Treat idiopathic Parkinson's disease (PD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$186.5M

$11.5M

$175.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/20/2010

$186.5M

$11.5M

$175.0M

Get a free BioCentury trial today